{"id":"methylphenidate-mpd","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"10-20","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that inhibits the reuptake transporters (DAT and NET) for dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control in patients with attention deficit hyperactivity disorder and narcolepsy.","oneSentence":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:45.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT00359723","phase":"PHASE2","title":"Methylphenidate and Parkinson's Disease","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2004-07","conditions":"Parkinson's Disease","enrollment":13},{"nctId":"NCT00526630","phase":"PHASE4","title":"Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2007-12","conditions":"Parkinson's Disease, Gait Impairment","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":155,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ritalin"],"phase":"marketed","status":"active","brandName":"Methylphenidate (MPD)","genericName":"Methylphenidate (MPD)","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate blocks the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability in the brain. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}